Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Short Course Radiotherapy and Consolidation Chemotherapy in Rectal Cancer
NCT04231552Phase 2Unknown
- Start
- Nov 2019
- Primary completion
- Sep 2020
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in rectal cancer. Primary endpoint: Pathological Complete Response at 1 year. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04231552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04231552.